Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 172
Inquire Before Buying

Global Markets Direct's, ‘Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016', provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer

  • The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects

  • The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Human Papillomavirus (HPV) Associated Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Overview 10
Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis 11
Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 12
Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 15
Human Papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Human Papillomavirus (HPV) Associated Cancer - Products under Development by Companies 19
Human Papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 22
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 23
Admedus Ltd 23
Advaxis, Inc. 24
Antigen Express, Inc. 25
Bionor Pharma ASA 26
BioNTech AG 27
Cancer Research Technology Limited 28
Cell Medica Limited 29
Etubics Corporation 30
EyeGene, Inc. 31
Formune S.L. 32
Genexine, Inc. 33
Genticel S.A. 34
iBio, Inc. 35
Immunovaccine, Inc. 36
Inovio Pharmaceuticals, Inc. 37
Inthera Bioscience AG 38
Johnson & Johnson 39
Karyopharm Therapeutics, Inc. 40
Kite Pharma, Inc. 41
MedImmune, LLC 42
Novartis AG 43
Onconova Therapeutics, Inc. 44
Oryx GmbH & Co. KG 45
Profectus BioSciences, Inc. 46
Selecta Biosciences, Inc. 47
Shantha Biotechnics Limited 48
Sirnaomics, Inc. 49
Theravectys SA 50
THEVAX Genetics Vaccine USA Inc 51
Tomegavax, Inc. 52
Transgene SA 53
UbiVac, LLC 54
Vaccibody AS 55
Vault Pharma Inc. 56
Virometix AG 57
ViroStatics srl 58
VLPbio 59
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Target 61
Assessment by Mechanism of Action 63
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
ABI-1968 - Drug Profile 69
AEH-10p - Drug Profile 70
alpelisib - Drug Profile 71
Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 74
Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 75
BVAC-C - Drug Profile 76
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 77
Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 78
Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 80
CerviVax - Drug Profile 82
CMD-004 - Drug Profile 83
DPV-001 - Drug Profile 84
DPXE-7 - Drug Profile 86
EDA-HPVE7 - Drug Profile 87
EG-HPV - Drug Profile 88
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 89
ETBX-041 - Drug Profile 90
GTL-001 - Drug Profile 91
GTL-002 - Drug Profile 94
GX-188E - Drug Profile 95
human papillomavirus (7-valent) vaccine - Drug Profile 97
human papillomavirus [Serotype 16] vaccine - Drug Profile 98
human papillomavirus [serotypes 16] vaccine - Drug Profile 99
human papillomavirus vaccine - Drug Profile 100
human papillomavirus vaccine - Drug Profile 101
human papillomavirus vaccine - Drug Profile 102
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 103
INO-3106 - Drug Profile 104
INO-3112 - Drug Profile 105
Lm-LLO-ISG15 - Drug Profile 107
LN-145 - Drug Profile 109
Monoclonal Antibody to Target E6 and E7 Proteins for Oncology - Drug Profile 111
NIT-02 - Drug Profile 112
NP-001 - Drug Profile 113
PVX-01 - Drug Profile 114
Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 115
Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 116
rigosertib sodium - Drug Profile 117
sdCMV-002 - Drug Profile 128
SEL-701 - Drug Profile 129
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 130
Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile 131
STP-909 - Drug Profile 132
Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile 133
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 134
TA-CIN - Drug Profile 135
TG-4001 - Drug Profile 136
TVGV-1 - Drug Profile 138
Vacc-HPV - Drug Profile 139
Vaccine for HIV and HPV Associated Cancer - Drug Profile 140
Vaccine for HPV Associated Cancer - Drug Profile 141
Vaccine for HPV Associated Cancers - Drug Profile 142
Vaccine for HPV Associated Cervical Cancer - Drug Profile 143
Vaccine for HPV Associated Cervical Cancer - Drug Profile 144
Vaccine for HPV Associated Cervical Cancer - Drug Profile 145
Vaccine for HPV Associated Skin Cancer - Drug Profile 146
Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile 147
VB-1016 - Drug Profile 148
verdinexor - Drug Profile 150
VGX-3100 - Drug Profile 151
Vicoryx - Drug Profile 154
VMT-2 - Drug Profile 155
VPI-241 - Drug Profile 156
Vvax-001 - Drug Profile 157
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 158
Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 160
Featured News & Press Releases 160
Appendix 167
Methodology 167
Coverage 167
Secondary Research 167
Primary Research 167
Expert Panel Validation 167
Contact Us 167
Disclaimer 168

List of Tables

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016 14
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Investigation by Universities/Institutes, H2 2016 26
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2016 27
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H2 2016 28
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2016 29
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2016 30
Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2016 31
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H2 2016 32
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cell Medica Limited, H2 2016 33
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2016 34
Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2016 35
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2016 36
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2016 37
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genticel S.A., H2 2016 38
Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2016 39
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H2 2016 40
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 41
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inthera Bioscience AG, H2 2016 42
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2016 43
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 44
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H2 2016 45
Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2016 46
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H2 2016 47
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2016 48
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016 49
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H2 2016 50
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences, Inc., H2 2016 51
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H2 2016 52
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2016 53
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H2 2016 54
Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016 55
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Tomegavax, Inc., H2 2016 56
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2016 57
Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac, LLC, H2 2016 58
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2016 59
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc., H2 2016 60
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H2 2016 61
Human Papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics srl, H2 2016 62
Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H2 2016 63
Assessment by Monotherapy Products, H2 2016 64
Number of Products by Stage and Target, H2 2016 66
Number of Products by Stage and Mechanism of Action, H2 2016 68
Number of Products by Stage and Route of Administration, H2 2016 70
Number of Products by Stage and Molecule Type, H2 2016 72
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2016 162
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects (Contd..1), H2 2016 163

List of Figures

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016 14
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 64
Number of Products by Top 10 Targets, H2 2016 65
Number of Products by Stage and Top 10 Targets, H2 2016 65
Number of Products by Mechanism of Actions, H2 2016 67
Number of Products by Stage and Mechanism of Actions, H2 2016 67
Number of Products by Top 10 Routes of Administration, H2 2016 69
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 69
Number of Products by Top 10 Molecule Types, H2 2016 71
Number of Products by Stage and Top 10 Molecule Types, H2 2016 71
  • Global Circulating Tumor Cells Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Dec-2016        Price: US 3480 Onwards        Pages: 110
    This report mainly covers Circulating Tumor Cells products, by types (CTC enrichment, CTC detection and CTC analysis), by applications (Prostate Cancer, Breast Cancer, Colorectal Cancer Diagnosis and Treatment and Others). Scope of the Report: This report focuses on the Circulating Tumor Cells in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, ty......
  • United States Non-small Cell Lung Cancer Therapeutics Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Non-small Cell Lung Cancer Therapeutics Revenue, means the sales value of Non-small Cell Lung Cancer Therapeutics This report studies sales (consumption) of Non-small Cell Lung Cancer Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Onco......
  • Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 477
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfo......
  • Small-Cell Lung Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 588
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spr......
  • Gallbladder Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 74
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts......
  • Vaginal Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2016, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment include......
  • Epithelial Ovarian Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 507
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape.Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, p......
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 463
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resis......
  • Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 108
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs